Vivaldi Biosciences
Chemicals & Related Products · Colorado, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3185-a Rampart Rd, Fort Collins, Colorad...Phone Number
(970) 492-4366Website
www.vivaldibiosciences.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Vivaldi Biosciences
Vivaldi Biosciences is focused on developing nasal-spray, self-adjuvanting vaccines for viral respiratory diseases using their Delta NS1 technology platform. Their key products include DeltaFLU, a universal influenza vaccine in Phase 2 clinical development, and Delta-19, a combination vaccine for Covid-19 and influenza. The Delta NS1 platform is designed to induce a robust immune response while ensuring safety by being replication-deficient and non-shedding. The company aims to provide broad protection against both epidemic and pandemic viral respiratory diseases.Explore more
Vivaldi Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vivaldi Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Vivaldi Biosciences
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Vivaldi Biosciences recently announced quarterly report
Click to see if Vivaldi Biosciences had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Vivaldi Biosciences has new funding data
Vivaldi Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Vivaldi Biosciences is spiking on competitors!
Check if Vivaldi Biosciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Vivaldi Biosciences launches new products
Recommended Actions
Find VP level buyers at Vivaldi Biosciences
Find 3 more new buyers
Compare Similar Companies to Vivaldi Biosciences
Compare insights from companies similar to Vivaldi Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vivaldi Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vivaldi Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vivaldi Biosciences.
Vivaldi Biosciences financials insights
Gather financial insights about Vivaldi Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Series A
$23M
Vivaldi Biosciences Tech Stack
A closer look at the technologies used by Vivaldi Biosciences
Vivaldi Biosciences News & Media
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vivaldi Biosciences
Sign Up For FreeTo access detailed company insights
Vivaldi Biosciences is focused on developing nasal-spray, self-adjuvanting vaccines for viral respiratory diseases using their Delta NS1 technology platform. Their key products include DeltaFLU, a universal influenza vaccine in Phase 2 clinical development, and Delta-19, a combination vaccine for Covid-19 and influenza. The Delta NS1 platform is de... Read More
